Human B-Raf Antibody

Detection of Human B-Raf by Western Blot. Western blot shows lysates of T47D human breast cancer cell line, MDA-MB-453 human breast cancer cell line, Daudi human Burkitt's lymphoma cell line, MOLT-4 human acute lymphoblastic leukemia cell line and U266 human myeloma cell line. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human B-Raf Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3424) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). A specific band was detected for B-Raf at approximately 95 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Detection of Human B‑Raf by Simple Western^TM. Simple Western lane view shows lysates of T47D human breast cancer cell line, loaded at 0.2 mg/mL. A specific band was detected for B-Raf at approximately 95 kDa (as indicated) using 10 µg/mL of Goat Anti-Human B-Raf Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3424) followed by 1:50 dilution of HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

Detection of Human B‑Raf by Simple Western^TM. Simple Western lane view shows lysates of MOLT‑4 human acute lymphoblastic leukemia cell line, loaded at 0.2 mg/mL. A specific band was detected for B‑Raf at approximately 95 kDa (as indicated) using 10 µg/mL of Goat Anti-Human B‑Raf Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3424) followed by 1:50 dilution of HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

Detection of Human B-Raf by Western Blot Changes in ERK1/2 and MEK in response to PLX4032. (A) Melanoma cell strains were treated with DMSO for 4 h (0), or with PLX4032 (1 μM) for 4 and 8 h. The panels show Western blots probed with antibodies to phosph-ERK1/2 Thr202/Tyr204 mAb (pERK), ERK1/2 (ERK), phospho-MEK1/2 (pMEK), MEK1/2 (MEK), and actin as a loading control. The mutation status of BRAF, NRAS, PTEN and beta -catenin ( beta CAT) are indicated at the top. (B) Western blot analyses of ERK1/2 inactivation/activation after short-term incubation with PLX4032 (1 μM). (C) pERK1/2 and ERK1/2 in supernatant (Sup) and particulate (Part) fractions. (D) Changes in pERK1/2 activation after treatments with increasing concentration of PLX4032, or DMSO for 1 h. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/20149136), licensed under a CC-BY license. Not internally tested by R&D Systems.